| answer text |
<p>The Department continues to examine the potential introduction of prophylaxis,
which includes deployment and administration processes. On 17 March 2022, Evusheld
was granted conditional marketing approval by the Medicines and Healthcare products
Regulatory Agency. However, the approval highlighted uncertainty over the dose required
for protection against the Omicron variants.</p><p>We have asked clinicians to advise
on the most appropriate option for the National Health Service in line with all available
data, the public health situation and other treatments available.</p><p> </p>
|
 |
